Opinion

Video

Shared Decision-Making for IgAN Treatment

Key Takeaways

  • Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
  • Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
SHOW MORE

Panelists discuss how shared decision-making is essential when considering emerging treatments vs established therapies, emphasizing the importance of aligning treatment choices with patient preferences and values to enhance adherence and optimize outcomes in IgA nephropathy care.

  1. What role does shared decision-making play when considering emerging treatments vs established therapies?
Related Videos
New Buprenorphine Label Allows Physician-Informed Treatment of Opioid Use Disorder, with Bobby Mukkamala, MD
Jonathan Stine, MD, MSc | Credit: AASLD
Christina Druskovich: A Mentorship Opportunity with the Society for Pediatric Dermatology
Evaluating the Medtronic 780G System in Type 2 Diabetes | Image Credit: HCPLive
Understanding Omnipod 5 AID and SECURE-T2D | Image Credit: HCPLive
© 2025 MJH Life Sciences

All rights reserved.